Contact Information: CONTACT: Joseph K. Belanoff, M.D. Chief Executive Officer Corcept Therapeutics 650-327-3270 www.corcept.com
Corcept Therapeutics Completes Second Closing Under August Private Equity Financing Agreement
| Source: Corcept Therapeutics
MENLO PARK, CA--(Marketwire - September 25, 2007) - Corcept Therapeutics Incorporated (NASDAQ : CORT ) today announced the successful completion of the second closing as
part of the private placement financing agreement dated August 16, 2007.
On August 20, 2007, the Company announced that it had entered into a
financing agreement to sell a total of approximately 4.8 million shares of
its common stock at a price of $2.10 per share, pursuant to a definitive
agreement dated as of August 16, 2007 entered into with accredited
investors. The Company completed the initial closing of the financing on
August 17, 2007, selling approximately 3.6 million shares of its common
stock at the purchase price of $2.10 per share for proceeds of $7.6
million. The investors in the initial closing included Paperboy Ventures
LLC, who is currently the largest shareholder of Corcept, Sutter Hill
Ventures and Alta Partners, LLP, venture capital firms that are currently
significant shareholders in Corcept, and various entities and individuals
related to these firms, members of the Corcept Board of Directors, Joseph
C. Cook, Jr., David L. Mahoney, G. Leonard Baker and James N. Wilson, and
other accredited investors.
On September 24, 2007, after receiving approval at a special meeting of
stockholders, the Company completed the second closing under this financing
agreement, selling an additional 1.2 million shares of common stock at the
purchase price of $2.10 per share to Paperboy Ventures LLC to fulfill its
remaining commitment for additional proceeds of $2.5 million. After
completing this second closing, gross proceeds to Corcept as a result of
this financing round totaled $10.1 million.
Corcept intends to use the proceeds of this financing to conduct the next
Phase 3 clinical trial evaluating CORLUX® for the treatment of the
psychotic features of psychotic depression, to conduct studies to extend
and confirm the results of its recent study of CORLUX for the management of
antipsychotic-induced weight gain, to continue development of its new
chemical entities and for general corporate purposes, including working
capital.
The securities sold and issued in connection with the private placement
have not been registered under the Securities Act of 1933, as amended, or
any state securities laws and may not be offered or sold in the United
States absent registration with the Securities and Exchange Commission or
an applicable exemption from the registration requirements. As part of the
transaction, Corcept has agreed to file a registration statement with the
Securities and Exchange Commission for purposes of registering the resale
of all of the common stock issued in the private placement within two
business days following the filing of its Form 10-K for its fiscal year
ending December 31, 2007.
This news release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such
state. Any offering of Corcept Therapeutics Incorporated common stock under
the resale registration statement will be made only by means of a
prospectus.
Statements made in this news release, other than statements of historical
fact, are forward-looking statements. Such statements include, without
limitation, the intended use of the proceeds from the offering and the
projected date for the filing of a registration statement for resale of the
shares that have been sold. Forward-looking statements are subject to a
number of known and unknown risks and uncertainties that might cause actual
results to differ materially from those expressed or implied by such
statements. These and other risk factors are set forth in the Company's SEC
filings, all of which are available from our website (www.corcept.com) or
from the SEC's website (www.sec.gov). We disclaim any intention or duty to
update any forward-looking statement made in this news release.